Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Giving temozolomide together with bevacizumab
may kill more tumor cells.
PURPOSE: This phase II trial is studying giving temozolomide together with bevacizumab to see
how well they work in treating patients with metastatic melanoma of the eye.